(original) (raw)

TY - JOUR AU - Schechter, Meir AU - Melzer Cohen, Cheli AU - Fishkin, Alisa AU - Rozenberg, Aliza AU - Yanuv, Ilan AU - Sehtman-Shachar, Dvora R. AU - Chodick, Gabriel AU - Clark, Alice AU - Abrahamsen, Trine J. AU - Lawson, Jack AU - Karasik, Avraham AU - Mosenzon, Ofri PY - 2023 DA - 2023/05/27 TI - Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence JO - Cardiovascular Diabetology SP - 126 VL - 22 IS - 1 AB - In clinical trials enrolling patients with type 2 diabetes (T2D) at high cardiovascular risk, many glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improved albuminuria status and possibly mitigated kidney function loss. However, limited data are available regarding the effects of GLP-1 RAs on albuminuria status and kidney function in real-world settings, including populations with a lower baseline cardiovascular and kidney risk. We assessed the association of GLP-1 RAs initiation with long-term kidney outcomes in the Maccabi Healthcare Services database, Israel. SN - 1475-2840 UR - https://doi.org/10.1186/s12933-023-01829-0 DO - 10.1186/s12933-023-01829-0 ID - Schechter2023 ER -